Implications of all the available evidence
CKD, acute kidney injury, albuminuria
CARDIOVASCULAR DISEASE
These results suggest that empagliflozin slows the rate of progression of CKD in
a broad range of patients. The findings challenge guidelines which have used
albuminuria to stratify their level of recommendation about who should be
treated with SGLT2 inhibitors. Patients with lower albuminuria (and consequently
at lower risk of progression of CKD) benefit from treatment with SGLT2
inhibition in terms of preservation of kidney function, in addition to
reductions in risk of acute kidney injury and cardiovascular disease.